scispace - formally typeset
B

Bernd Meibohm

Researcher at University of Tennessee Health Science Center

Publications -  189
Citations -  9431

Bernd Meibohm is an academic researcher from University of Tennessee Health Science Center. The author has contributed to research in topics: Pharmacokinetics & Population. The author has an hindex of 47, co-authored 172 publications receiving 8250 citations. Previous affiliations of Bernd Meibohm include University of South Carolina & National Institutes of Health.

Papers
More filters
Journal ArticleDOI

Pharmacokinetics of Monoclonal Antibodies

TL;DR: This tutorial will review major drug disposition processes relevant for mAbs, and will highlight product‐specific and patient‐specific factors that modulate their pharmacokinetic (PK) behavior and need to be considered for successful clinical therapy.
Journal ArticleDOI

How Important Are Gender Differences in Pharmacokinetics

TL;DR: Gender-related differences in pharmacokinetics have frequently been considered as potentially important determinants for the clinical effectiveness of drug therapy and intensive future research efforts are needed to assess the full scope and impact of pharmacodynamic gender disparity on applied pharmacotherapy.
Journal ArticleDOI

Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function

María Soler Artigas, +192 more
- 01 Nov 2011 - 
TL;DR: This article identified new regions showing association with pulmonary function in or near MFAP2, TGFB2, HDAC4, RARB, MECOM (also known as EVI1), SPATA9, ARMC2, NCR3, ZKSCAN3, CDC123, C10orf11, LRP1, CCDC38, MMP15, CFDP1 and KCNE2.
Journal ArticleDOI

Population pharmacokinetics of therapeutic monoclonal antibodies.

TL;DR: Many features of the population pharmacokinetics of currently used therapeutic mAbs are similar, despite differences in their pharmacological targets and studied patient populations.
Journal ArticleDOI

Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives.

TL;DR: Pharmacokinetic/pharmacodynamic (PK/PD)-modeling links dose-concentration relationships (PK) and concentration-effect relationships (PD), thereby facilitating the description and prediction of the time course of drug effects resulting from a certain dosing regimen as discussed by the authors.